Advanced Treatments for Type 1 Diabetes: New Hopes
Daily blood glucose control and dependence on insulin injections pose a constant physical and emotional burden on people with type 1 diabetes. However, recent years have brought significant scientific breakthroughs that are gradually shifting the treatment paradigm for this chronic autoimmune condition. Modern science is moving from symptomatic control toward disease modification and restoring the body's ability to produce insulin independently.
Cell Therapy: Insulin Without Injections
Pancreatic islet cell transplantation has long been considered a promising avenue, but the shortage of donor organs limited its application. A breakthrough in this field came with cells grown in the laboratory from stem cells. At the American Diabetes Association (ADA) annual scientific sessions in June 2025, Vertex presented results of a clinical trial for VX-880 (zimislecel), which were also published in The New England Journal of Medicine (NEJM). All 12 participants in the Phase I/II trial who received a full dose and were monitored for at least a year achieved the target glycated hemoglobin (HbA1c) level of less than 7% and spent over 70% of the time within the target glucose range. Furthermore, 10 out of the 12 patients completely stopped daily insulin injections. Although these results are impressive, this therapy still requires continuous suppression of the patient's immune system with immunosuppressive drugs to protect the new cells from rejection.
Cell Disguise: Transplantation Without Immunosuppression
The main obstacle to the widespread adoption of cell therapy is the risks associated with lifelong immunosuppression. To address this issue, scientists are developing methods of genetic cell modification to "hide" them from the immune system. In July 2026, The New England Journal of Medicine (NEJM) published 14-month follow-up data of a patient who was transplanted with experimental UP421 cells from Sana Biotechnology at Uppsala University Hospital in Sweden. Thanks to the hypoimmune platform (HIP) technology, the cells were engineered to evade autoimmune attack. Fourteen months post-transplantation, these cells continued to survive and successfully produced C-peptide (a marker of endogenous insulin production) in response to food intake, while the patient received no immunosuppressive drugs. This outcome opens the way for safer and more accessible cell therapies.
Immunotherapy: Delaying the Onset of the Disease
Another critical direction is halting the autoimmune process in its early stages, before the complete destruction of beta cells. A major step forward was the approval of teplizumab (Teplizumab) by the US Food and Drug Administration (FDA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in August 2025. As noted in a 2025 review in The Lancet led by Professor Anette-Gabriele Ziegler from the Helmholtz Munich Diabetes Center, teplizumab is the first approved immunotherapy capable of delaying the onset of clinical stage 3 type 1 diabetes in high-risk individuals. The drug works by partially suppressing T-cells that mistakenly attack the pancreas, thereby preserving residual beta-cell function and buying valuable time without the immediate need for insulin therapy.
Practical Conclusion
Although these advanced therapies are still undergoing clinical trials and are not yet widely available, they clearly demonstrate that science is steadily moving toward overcoming type 1 diabetes. For patients and their families, this underscores the importance of preventive screening for autoantibodies, especially in the presence of a family history of the disease. Early detection of autoimmune markers allows identifying the risk long before the first symptoms appear. Any decisions regarding participation in clinical trials or changing the current treatment regimen should be made exclusively upon doctor's recommendation.
Sources
The Lancet. The future of type 1 diabetes therapy (2025)
NEJM. Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes (2025)
Breakthrough T1D. Tegoprubart Islet Transplant: All Participants Off External Insulin (2026)
